Attention is now turning to a harder question: what changes after AI enters the working environment?

For healthcare organisations, the answer cannot be limited to how many tools have been launched or how many employees have been trained. AI must eventually show its value through better use of staff time, more dependable workflows, faster access to relevant information and improvements that can be observed in routine service delivery.

This shift is already visible across the UAE. Health authorities are paying closer attention to institutional adoption, workforce capability, data governance, service performance and continuous evaluation. The discussion is becoming less about proving that AI can perform a task and more about determining whether it can perform that task reliably within a healthcare system.

The UAE is moving beyond isolated use cases

Pilot projects have played an important role in the UAE’s digital health development. They allowed providers to test new approaches without immediately committing them to larger operational environments. They also helped build familiarity with AI among clinicians, administrators, policymakers and patients.

A pilot, however, provides only a partial view of performance. It usually operates within a defined scope, with selected users and close technical support. Healthcare operations are less controlled. Patient volumes change, information arrives in different formats, exceptions occur frequently and teams must balance several priorities at once.

A system that succeeds in a demonstration may behave differently when it is connected to established processes, legacy systems and daily workloads. It may perform its central function well but still require staff to verify information, correct outputs or complete unresolved work through another channel.

The current policy direction in the UAE acknowledges this gap. In February 2026, the Ministry of Health and Prevention convened federal and local health authorities, academic institutions and technology organisations to help develop a national policy for smart health services and AI. The proposed policy addresses data quality, privacy, workforce skills, governance, infrastructure and the measurement of effects on public health and patient experience.

Of particular importance is the inclusion of national performance indicators and ongoing evaluation. This suggests that AI adoption is being considered as a long-term institutional responsibility rather than a series of unrelated technology projects.

That distinction should shape how healthcare organisations make investment decisions. The question is not only whether an AI application can be deployed. Leaders must understand whether it can become a stable part of the organisation, with clear ownership, suitable data, defined escalation routes and measurable objectives.

Productivity should begin with the pressure on healthcare teams

Productivity can be a difficult word in healthcare. Used carelessly, it may suggest that clinicians should see more patients in less time or that administrative teams should process higher volumes with fewer people. Neither interpretation captures the real opportunity.

The more useful definition concerns capacity. Where are skilled employees spending time on work that does not require their expertise? Which delays are created by missing information, repeated checks or unnecessary handoffs? Where does routine administration prevent a team from responding to more complex needs?

AI can support productivity when it gives usable time back to the organisation. This may come from reducing repetitive documentation, identifying cases that require attention, preparing information before a consultation or helping managers see operational problems earlier.

The value does not lie in time savings alone. It lies in what the organisation is then able to do with that time.

A clinician who receives a useful summary before meeting a patient may be able to focus more closely on the consultation. An operations team alerted to a service issue before it escalates may resolve it with less effort. An administrator freed from repeated information entry may have more capacity to manage cases that require judgment or direct communication.

Dubai Health Authority’s Risk Radar system offers a current example of this principle. The system analyses calls to the authority’s customer service centre using factors such as call quality, sentiment, contact frequency and service data. Cases that may require attention are referred to the operations team for follow-up. DHA reported in February 2026 that negative calls identified by the system had fallen by more than 81 percent over eight months.

The significant point is not simply that AI analyses conversations. It connects analysis with an operational response. Supervisors receive information that can influence what their teams do next.

This is a more meaningful test of productivity. The technology does not merely generate an output. It helps the organisation direct attention toward the interactions that need it most.

The workflow must be evaluated as a whole

One of the most common weaknesses in AI adoption is the tendency to evaluate the tool separately from the process around it. A model may achieve a strong accuracy result while the overall workflow remains slow, fragmented or difficult for employees to manage.

Healthcare leaders should therefore examine the full path of work. How does information reach the AI system? Is the output delivered inside the platform employees already use? Who reviews it? What happens when the information is incomplete? Can staff identify why a case was flagged? Where does responsibility sit if the result is wrong?

These questions often reveal more about likely operational value than a technical performance score.

A system that saves two minutes at one stage but creates five minutes of checking elsewhere has not improved productivity. Nor has a system that moves work from one team to another without reducing the total effort required. The same applies when employees must maintain parallel manual records because they do not fully trust the digital process.

This is why frontline knowledge matters. Formal workflow diagrams rarely show every practical decision made during a working day. Nurses, physicians, patient-access teams and administrators know where information is usually missing, which cases produce exceptions and which tasks depend on individual experience.

Their involvement should extend beyond user testing at the end of a project. They should help define the problem, assess how the work currently happens and identify what a useful result would look like.

Emirates Health Services’ recent AI initiatives illustrate the breadth of workflows now being considered in the UAE. The organisation has presented applications supporting virtual urgent care, clinical information preparation, safety monitoring, early detection and nursing workforce assessment. In its February 2026 announcement, EHS described a move from separate solutions toward a more connected system involving prediction, early intervention and service design.

The operational challenge will be to ensure that these applications do not remain individual technology layers. Their value will depend on how well they connect with clinical responsibilities, staff decisions and existing information systems.

The most useful measures are often close to the work

Healthcare AI programmes frequently begin with broad targets such as improving efficiency, enhancing experience or supporting better decisions. These goals are reasonable, but they are difficult to manage unless they are translated into measures that reflect the actual workflow.

A hospital introducing AI into a scheduling process might examine the time taken to confirm an appointment, the number of manual interventions required and the rate of unresolved requests. A clinical support application might be assessed through the quality of information prepared, the frequency of corrections and whether clinicians receive it at the right point in their work.

Average performance is not enough. Leaders should also understand variation. Does the system work equally well across facilities, patient groups and service types? Which cases require the most human intervention? How often do employees override an output, and why?

These are not minor technical details. They show whether the application can be trusted under the conditions in which healthcare is actually delivered.

Every programme should begin with a baseline. If an organisation cannot describe the original cost, delay, effort or failure point, it will struggle to demonstrate that AI improved it. Measurement should also continue well after launch because workloads, data and employee behaviour change over time.

Abu Dhabi’s Responsible AI Standard provides a strong foundation for this approach. It applies to AI used in clinical, financial and administrative functions by licensed healthcare entities. The standard requires designated ownership, monitoring of outputs and exceptions, review of override events, traceable decisions, human oversight and escalation mechanisms.

These requirements move AI governance closer to everyday operations. Responsibility cannot sit with a temporary project team once a system goes live. Someone must remain accountable for how it performs, how problems are identified and how decisions are made when the technology does not behave as expected.

Workforce readiness is more than AI training

The UAE has invested heavily in developing digital and AI capabilities. The next requirement is to connect those capabilities to the work performed inside healthcare organisations.

Employees do not need the same level of technical knowledge, but they do need clarity about how AI affects their responsibilities. A clinician must know when an AI-generated suggestion requires further review. An administrator must understand what to do when information is missing. A manager must be able to determine whether a reported efficiency gain has simply shifted work elsewhere.

This calls for more than product instruction. It requires practical judgment.

Healthcare employees should be able to question outputs without being treated as resistant to innovation. They should know where to report recurring problems and whether their feedback leads to a change in the system or workflow. Managers should be prepared to stop or redesign an application when it creates more work than it removes.

Leadership language matters here. Employees are unlikely to support AI simply because it is described as advanced. They need to understand the operational reason for its introduction and how its use will improve the work.

A credible implementation should be able to answer three questions for staff: which problem is being addressed, which parts of the job will change and where human responsibility remains essential.

This is especially important in healthcare because productivity cannot come at the expense of professional accountability. AI may support faster decisions, but speed does not reduce the need for judgment. It may prepare information, but the availability of a summary does not guarantee that the information is complete or relevant.

Organisations that build this distinction into their training and management practices are more likely to achieve lasting adoption than those that focus mainly on system usage.

Healthtech companies will face a higher standard of proof

As the UAE healthcare market becomes more outcome-focused, technology companies will need to change how they present and support AI.

A product demonstration can show what a system is capable of doing. It cannot show how the system will perform inside every provider environment. That depends on local data, system architecture, process design, staffing and service expectations.

Healthtech companies should therefore be prepared to discuss operational limitations openly. Providers need to know which situations require human review, how exceptions are managed, what integration effort is involved and how performance will be monitored after deployment.

The commercial relationship should not define success as the date the system becomes active. Nor should it rely only on the number of users or transactions. Those figures may show that a solution is present, but they do not show that it is useful.

A stronger approach is to agree on a small set of operational outcomes before implementation. These should be relevant to the problem, measurable with available data and reviewed jointly by the provider and technology company.

This creates shared accountability. The provider remains responsible for clinical and operational decisions. The technology company remains responsible for understanding how its system performs and for addressing limitations that emerge in use.

The UAE’s connected digital health ecosystem offers a suitable environment for this model. Government bodies, providers, universities and private companies already work closely across many AI initiatives. The opportunity now is to make operational evidence a central part of those partnerships.

The next benchmark is sustained usefulness

The UAE has no shortage of healthcare AI ambition. Its institutions have demonstrated a willingness to test technology, build policy frameworks and invest in digital capability. The next source of leadership will come from showing how AI performs after the excitement of launch has passed.

Some projects will produce clear gains and move into wider use. Others may need to be narrowed, redesigned or discontinued. That should be regarded as sound management, not a loss of momentum. A mature healthcare AI environment must be able to distinguish between a promising demonstration and a dependable service.

The strongest evidence of progress will be found inside ordinary working days: fewer avoidable handoffs, earlier identification of problems, better use of specialist time and more consistent service for patients.

Those outcomes may attract less attention than a major technology announcement, but they matter more to healthcare organisations.

The UAE has already shown that it can move quickly in healthcare innovation. Its next task is to prove that speed can be matched by discipline, accountability and sustained usefulness. That is where AI begins to create productivity that the healthcare system can genuinely use.

Author bio:
Inger Sivanthi is the Chief Executive Officer of Droidal, an AI healthcare services company focused on revenue cycle and operational automation. With expertise in large language models and applied AI, he has helped healthcare organizations achieve over $250 million in cost savings through intelligent AI agents. His work focuses on responsible AI adoption that improves healthcare operations and financial outcomes at scale.

The post UAE Healthcare AI Is Moving from Pilot Projects to Productivity Outcomes appeared first on DH Arab.

The New York and Dubai-based brain measurement company has announced the launch of Brainify.AI Longevity at The Longevity Suite in Riyadh, marking the first deployment of its new platform designed specifically for luxury wellness and longevity centers. The partnership introduces what the company describes as Riyadh’s first luxury brain wellness assessment experience, using non-invasive brainwave technology to generate clinical-grade cognitive data for general wellness clients.

“Longevity has done an extraordinary job measuring and improving physical health, but cognitive health has remained one of the most under-served areas, even though it’s exactly what clients are asking about,” said Ivan Mishanin, Co-Founder and COO of Brainify.AI. The Longevity Suite, which operates clinics in Europe and the Middle East, already offers programmes in cryotherapy, IV therapy, hyperbaric oxygen, and advanced diagnostics. Adding brain measurement, the company says, is a natural extension of that model.

How does it work?

The assessment takes ten minutes. A client undergoes a non-invasive brainwave scan, and the system produces a Brain Wellness Report with the following outputs:

• A Brain Vitality Score and estimated brain age
• Metrics across focus, stress resilience, and cognitive clarity
• Results benchmarked against age and sex norms drawn from Brainify.AI’s proprietary database of over 500,000 brain scans
• A personalised wellness roadmap, with the option to track changes across repeat sessions

The technology behind the product was originally developed for pharmaceutical research and hospital settings. Brainify.AI has repackaged it into a consumer-facing format under the Brainify.AI Longevity platform, which includes a co-branded Brain Wellness Report, a guided assessment workflow, and access to normative data from the company’s Datahub. Each wellness partner essentially receives a white-labelled cognitive health service built on clinical infrastructure.

Why does it matter?

The Saudi wellness market is growing fast, driven in part by Vision 2030’s emphasis on preventive health, quality of life, and diversifying the economy beyond oil. Riyadh in particular has seen a wave of investment in premium health and longevity concepts over the past two years. But cognitive health, as Mishanin points out, has lagged behind physical health metrics in most of these offerings.

Bringing a standardised, data-driven brain assessment into a luxury clinical environment changes that. It gives practitioners something concrete to work with, and it gives clients a measurable baseline. That’s not a small thing. Cognitive decline is one of the most feared health outcomes globally, and demand for early insight, well before symptoms appear, is rising sharply across high-income demographics. The GCC, with its concentration of affluent, health-conscious consumers and its broader push toward preventive medicine, is a logical market for this kind of product.

The Riyadh site will operate as a flagship location, with plans to expand to additional Longevity Suite clinics across the GCC.

The context

Brainify.AI’s broader infrastructure covers clinical data acquisition through its Brain Test product, standardised processing through its Datahub, and AI-driven research through what it calls its Foundational Brain Model. The company works with pharmaceutical clients and research institutions as well as wellness centres. The Longevity platform is effectively the consumer-facing arm of that stack.

The timing is deliberate. Health technology companies with clinical roots are increasingly looking at the Gulf as a commercialisation market, particularly as Saudi Arabia and the UAE invest heavily in digital health infrastructure and preventive care programmes. For Brainify.AI, Riyadh is not just a new geography. It is a proof point for a product category that does not yet have an established competitor in the region.

The post Brainify.AI brings brain wellness scoring to Riyadh in first GCC deployment appeared first on DH Arab.

What’s the news?

Crown Prince Al Hussein bin Abdullah II, serving as Regent, chaired a meeting of Jordan’s National Council for Future Technology on Tuesday, where he called for expanding the number of hospitals and health centres connected to the Jordan Digital Health Centre. Prime Minister Jafar Hassan, who chairs the council, was also present.

Minister of Health Ibrahim Bdour gave a progress report on the centre’s first year of operations, detailing the services it currently delivers across the country. Those include:

• A dialysis unit and intensive care unit linked to 12 hospitals
• A digital radiology unit connected to 19 hospitals
• A telemedicine unit linked to three healthcare centres
• More than 45,000 teleradiology reports delivered
• Over 55,000 dialysis sessions remotely monitored
• More than 2,000 ICU cases supervised
• Hundreds of specialist consultations extended to affiliated facilities

The Crown Prince stressed the need to keep building on the centre’s technological capabilities to improve services for citizens and reduce pressure on the health system.

Why does it matter?

Remote care is only as useful as its reach. Right now, the Jordan Digital Health Centre’s telemedicine unit covers three health centres. Its dialysis and ICU monitoring reaches 12 hospitals. That’s a solid foundation, but Jordan has over 100 public hospitals and hundreds of primary care facilities. The push from the palace to expand integration is essentially a directive to close that gap.

The efficiency case is also strong. Bdour pointed to improved resource management of medical supplies and hospital beds as a measurable benefit, which translates to real savings in government hospital budgets. For a country that has long worked to stretch its healthcare spending, that’s a meaningful outcome. And by reducing the need for patients to travel to specialist centres, the telemedicine component directly addresses one of the most persistent frustrations in public healthcare across the region.

The context

Jordan isn’t alone in this direction. Across the GCC and the broader Arab world, governments are moving to digitise and centralise health infrastructure. Saudi Arabia’s Vision 2030 has placed health technology at the centre of its reform agenda. The UAE has built out a network of smart health systems tied to its national digital identity framework. And Qatar has invested heavily in integrated health data platforms ahead of and following the 2022 World Cup.

Jordan’s approach is notable because it’s being driven from the top. Royal and prime ministerial involvement in a council dedicated to future technology signals that digital health isn’t being left to ministry-level bureaucracy alone. It has political priority. That tends to accelerate things.

Still, the real test will come in implementation. Connecting 12 hospitals to a dialysis network is one thing. Scaling that across a national system, with consistent data standards, trained staff, and reliable connectivity, requires sustained investment and coordination. The Crown Prince’s call for broader integration is a clear mandate. But what matters next is the plan to execute it, and the timeline attached to it.

For health system planners and technology vendors operating across the region, Jordan’s model is worth watching. It demonstrates that a mid-sized Arab economy can build functioning digital health infrastructure at scale, even within tight resource constraints. If the expansion goes well, it could offer a replicable blueprint for others in the region considering similar centralised care coordination models.

The post Jordan’s Crown Prince pushes for wider hospital integration into national digital health network appeared first on DH Arab.

The update, announced in Doha on 28 July 2026, introduces appointment confirmation, electronic fee payment, and direct access to radiology results, all from within the app. It is a focused, practical expansion rather than a wholesale redesign, and that focus is arguably what makes it useful.

How does it work?

The new features centre on three areas. First, patients can now confirm their upcoming appointments directly through Lbaih within the 48-hour window before their visit. Once that window opens, the ability to cancel or reschedule through the app is no longer available. Patients who still need to make changes during that period must contact the Nesma’ak service by calling 16060.

Second, as part of the first phase of the rollout, patients can pay applicable appointment fees electronically through the app. This feature is currently live at three HMC facilities:

• Heart Hospital
• Al Wakra Hospital
• Communicable Disease Center

Third, patients can now access their radiology results and full reports through the Medical File section of Lbaih. Reports from all HMC hospitals are available once a physician has reviewed and approved them, keeping clinical oversight in place while still getting results to patients faster.

Why does it matter?

For patients, the practical benefit is straightforward. Fewer phone calls, less time spent waiting for paper results, and a clearer picture of what happens in the lead-up to an appointment. But the operational angle is just as significant. Appointment no-shows are a persistent problem in public health systems globally. A built-in confirmation step, with a hard cutoff that pushes urgent changes to a live call centre, is a reasonable attempt to reduce that waste without creating new bottlenecks.

Nasser Al Naimi, Chief of Patient Experience at HMC and Director of Hamad Healthcare Quality Institute, said the features are designed to give patients “greater flexibility and control” over managing their care. Dr. Amal Gomaa Abdulla, HMC’s Chief Information Officer, pointed to the dual benefit: a better experience for patients and improved operational efficiency across facilities. She described Lbaih as “a single integrated platform” for secure, accessible digital health services, which signals that HMC sees the app as infrastructure, not just a convenience tool.

The context

Qatar is not operating in isolation here. Across the GCC, governments have spent the past several years pushing healthcare systems to digitise faster, driven partly by post-pandemic lessons and partly by national development frameworks that treat health technology as a strategic priority. In Qatar specifically, the national health strategy has consistently emphasised patient-centred care, and digital access is a core part of that commitment.

Lbaih launched in July 2025 and reached 300,000 downloads without a particularly long runway. That uptake reflects genuine demand, and it also puts some pressure on HMC to keep the platform’s capabilities growing at a pace that matches expectations. So far, this update suggests the organisation is treating the app as a live, evolving product rather than a one-time launch.

The phased rollout of electronic payments is also worth watching. Starting with three hospitals before expanding is a sensible approach that limits risk, but it also means the feature’s real-world performance at Heart Hospital, Al Wakra, and the Communicable Disease Center will effectively set the template for broader deployment. If the process holds up under real patient volumes, a wider rollout across HMC’s full network seems the logical next step.

For health system leaders watching from elsewhere in the Gulf, Lbaih is a useful data point in a larger conversation about what patients actually want from a public health app, and what it takes to get them to use one consistently.

The post HMC’s Lbaih app adds appointment confirmation and radiology results in latest update appeared first on DH Arab.

Sidra Medicine, a member of Qatar Foundation, administered the therapy in Doha on 28 July 2026, making it the first hospital in Qatar to do so and placing Qatar third in the world to use Itvisma. For a country that has invested heavily in precision medicine as part of its broader national health strategy, the milestone is meaningful. But for Khalid’s family, who spent years traveling internationally in search of answers, it means something more personal: advanced care, finally, at home.

How does it work?

Spinal muscular atrophy is a rare genetic neuromuscular disease caused by a missing or non-functioning SMN1 gene. Without it, the body cannot produce enough survival motor neuron protein, which is essential for motor neuron health and muscle function. Over time, the disease progressively weakens the muscles.

Itvisma, known generically as onasemnogene abeparvovec, addresses the root genetic cause. It delivers a functional copy of the human SMN1 gene through a single intrathecal injection, meaning it is administered directly into the spinal canal. This is not a treatment patients repeat. It is given once.

At Sidra Medicine, delivering that single injection required months of preparation and coordination across more than ten specialties, including:

• Genetics and Genomic Medicine
• Interventional Radiology
• Neurology and Anesthesiology
• Pediatric Intensive Care and Pulmonology
• Pharmacy, Physiotherapy, and Orthopedic Spine Services

Because Khalid has severe scoliosis, a common complication in SMA patients, the clinical team used real-time imaging during the procedure to guide needle placement with precision. Dr. Walid Mubarak, Senior Attending Physician in Interventional Radiology at Sidra Medicine, described the approach as critical: accurate delivery, in a complex anatomy, with no margin for error.

Why does it matter?

For years, SMA was managed rather than treated. Physicians focused on slowing progression and supporting function. Gene therapy changes that equation by targeting the disease at its source, not its symptoms.

Prof. Tawfeg Ben Omran, Division Chief of Genetics and Genomic Medicine at Sidra Medicine, noted that using interventional radiology for this kind of precision delivery places the hospital among the first pediatric centers in the world to adopt the approach, particularly for patients with complex spinal anatomy. That is not a minor distinction. SMA patients with severe scoliosis have historically faced barriers to intrathecal delivery, and Sidra’s capacity to manage that complexity opens the therapy to a broader patient group.

Itvisma is now registered with Qatar’s Ministry of Public Health, which means eligible patients can access it locally following specialist assessment. That matters in practical terms. Families no longer need to travel abroad for a therapy that, until now, was simply not available here.

The context

Qatar’s investment in genomic and precision medicine has been building steadily, anchored by institutions like Sidra Medicine and supported through the Qatar National Research Strategy. This administration of Itvisma is one visible output of that longer investment.

Across the Gulf, the picture is similar. Saudi Arabia’s Vision 2030 places health transformation at the center of national reform. The UAE has made genomics and AI-driven diagnostics central to its health system ambitions. Rare disease care, once an afterthought in regional health planning, is increasingly recognized as a marker of system maturity. A health system that can treat SMA with a one-time gene therapy, coordinated across a dozen specialties, under real-time imaging, is not a developing system. It is an advanced one.

Novartis, which produces Itvisma, has signaled continued commitment to expanding access across the GCC. Mohammed Ezz Eldin, Head of the GCC Cluster at Novartis, pointed to the milestone as evidence of what coordinated collaboration between industry and healthcare providers can produce for patients with significant unmet needs.

And Khalid, now recovering and still a high-achieving student at Qatar Academy Sidra, has already set his next goal. He wants to become a doctor to help other children like him. So the story does not end with the injection. It continues.

The post Sidra Medicine gives Qatar its first Itvisma gene therapy, making history for SMA care appeared first on DH Arab.

The device was created by a team led by Dr Khalid Abu Al Saud, a researcher and inventor at Qatar University, alongside four computer engineering students: Nora Al Bardini, Mazoon Al Shahwani, Fatima Al Kaabi and Sara Al Muhannadi. A US patent application has been published under the number US20240138776A, giving the project formal international recognition.

What started as a graduation project has grown into a dedicated research initiative, and in 2023 it won a gold medal at the International Invention Fair of the Middle East in Kuwait. That kind of recognition matters. It signals that the concept has been reviewed by peers in the region and found to be credible.

How does it work?

GlucoWatch uses artificial intelligence to estimate blood glucose by reading physiological signals from the body, specifically heart rate and blood pressure, combined with selected demographic data from the user. The device connects to a mobile application, where users can monitor their readings in real time.

The system also issues alerts when glucose levels fall outside medically approved ranges, and it allows users to share their health data with family members or healthcare providers, with privacy protections built in. According to Dr Abu Al Saud, the development process included:

• Designing the physical prototype of the wearable device
• Creating and training the AI algorithms used for glucose estimation
• Building the companion mobile application
• Conducting initial validation tests against conventional reference measurements

The team is now working to expand its database, improve its AI models, and produce a more advanced version of the device. Partnerships with healthcare and industrial organisations are also being explored, with the goal of producing a product that is commercially viable and affordable.

Why does it matter?

Non-invasive glucose monitoring has been a long-standing ambition in medical technology. Several large companies have tried and struggled to bring such a product to market at scale. The GlucoWatch team is not claiming they have solved that problem yet. But they are making measurable progress, and they are doing it from Doha.

For patients, the appeal is obvious. Eliminating the need for repeated finger pricks reduces pain, reduces cost over time, and may improve adherence to regular monitoring. And if the device can eventually integrate with digital health platforms and support remote care, it becomes relevant not just for individual patients but for health systems managing large diabetic populations.

The GCC has one of the highest rates of diabetes prevalence in the world. In Qatar, as in Saudi Arabia and the UAE, diabetes management is a major public health priority. A locally developed, affordable, non-invasive monitoring tool would address a real and documented gap.

The context

Dr Abu Al Saud has explicitly linked the project to Qatar National Vision 2030, which calls for investment in knowledge-based industries and locally driven innovation. That framing is important. Across the Gulf, governments are trying to build research ecosystems that produce applied outcomes, not just academic papers.

This project is a reasonable example of that model working. It originated in a university classroom, attracted student talent, earned international recognition, and is now moving toward commercial validation. The next phase, completing scientific validation and meeting regulatory requirements, will be the harder test. But the foundation is there.

For health policymakers and industry partners across the GCC, GlucoWatch is worth watching. It may not be on pharmacy shelves tomorrow. But it represents exactly the kind of home-grown health technology that Vision 2030 and similar national frameworks were designed to produce.

The post Qatar University’s GlucoWatch aims to end the finger-prick era of diabetes monitoring appeared first on DH Arab.

The technology allows physicians to access and biopsy small lung nodules in the peripheral areas of the lung, the deepest and most difficult sections to reach, without open surgery or major incisions. For patients, that means a faster diagnosis, less physical trauma, and a far shorter recovery time.

How does it work?

Robotic bronchoscopy uses a catheter system guided by a robotic arm and real-time imaging to travel through the airways and reach nodules that a standard bronchoscope simply cannot get to. The physician controls the system with precision, steering through narrow bronchial passages to the exact location of a suspicious nodule.

Once there, a tissue sample is taken for analysis. The whole procedure is minimally invasive. There are no large incisions, no general surgical risk, and patients typically go home the same day or shortly after. So compared to a surgical biopsy, the difference in patient experience is significant.

Why does it matter?

Early-stage lung cancer, when the tumour is still small and has not spread, carries a much higher survival rate than late-stage diagnoses. But early-stage nodules are precisely the ones that have been hardest to biopsy accurately. That diagnostic gap has real consequences: some patients face delayed diagnoses, others undergo more invasive procedures than necessary.

This technology addresses both problems. It gives pulmonologists and oncologists a reliable way to confirm or rule out malignancy in small, deep nodules at the point when a confirmed diagnosis matters most. And it does so without the recovery burden of open surgery.

For a region where non-communicable disease rates are high and health systems are actively working to shift toward earlier detection, that clinical advantage is worth paying attention to.

The context

This introduction fits a clear pattern across the UAE and the broader GCC. Under Abu Dhabi’s health strategy and Saudi Arabia’s Vision 2030, governments across the region have committed to reducing cancer mortality through prevention, screening, and early intervention. Bringing advanced diagnostic tools to the region, rather than requiring patients to travel abroad, is a direct expression of that ambition.

Cleveland Clinic Abu Dhabi has been central to the UAE’s effort to build a world-class clinical infrastructure locally. Adding the region’s first robotic bronchoscopy programme is consistent with that role.

Still, the real measure of success will be access. The technology exists. The question now is how many patients across the region can actually benefit from it, and how quickly screening programmes can identify the candidates who need it most.

The post Cleveland Clinic Abu Dhabi brings robotic bronchoscopy to the Middle East for the first time appeared first on DH Arab.

It is a concrete step, not a memorandum of understanding and not a pilot. The connection is active, and it allows physicians in both countries to work together in real time.

How will it work?

The integration creates direct communication channels between Seha Virtual Hospital, Saudi Arabia’s nationally operated virtual care platform, and Uzbekistan’s health system. Through these channels, Uzbek clinicians can reach Saudi specialists for consultations, diagnostic support, and treatment guidance around the clock. The system is designed to operate continuously, with no dependence on time zones or physical proximity.

The setup also opens a knowledge-transfer dimension. Uzbek healthcare professionals gain structured access to the clinical expertise sitting inside the Saudi system, which has spent several years building one of the region’s most advanced virtual care networks. So this is not simply a teleconsultation tool. It also has a capacity-building function built in from the start.

Why does it matter?

Seha Virtual Hospital has become one of the Kingdom’s most visible health infrastructure achievements. Launched under the Vision 2030 framework, it now connects dozens of hospitals across Saudi Arabia and handles thousands of consultations. Extending that network internationally, and to a country outside the Arab world, is a different kind of move entirely.

For Uzbekistan, the benefits are immediate. The country has been modernising its health sector rapidly, but specialist capacity remains uneven. Access to Saudi physicians in real time, particularly in critical care and complex diagnostics, addresses a practical gap.

For Saudi Arabia, the strategic value is just as clear. The Kingdom has stated openly that it wants to position itself as a global destination for health investment and cooperation. Deals like this one build that reputation more effectively than any conference announcement. And the choice of Uzbekistan, a country of 36 million people with strong regional ties across Central Asia, suggests Saudi health diplomacy is thinking beyond its immediate neighbourhood.

• Real-time cross-border consultations, diagnosis, and treatment support
• 24/7 availability with no geographical restrictions
• Direct access to Saudi specialist expertise for Uzbek clinicians
• Structured knowledge exchange and professional development pathways
• Full integration between Seha Virtual Hospital infrastructure and Uzbekistan’s national health systems

The context

This agreement fits into a broader Saudi push to export its health transformation model. Vision 2030 is not only about reforming healthcare inside the Kingdom. It explicitly calls for Saudi Arabia to become a hub for health investment and to build high-value international partnerships. A live digital link with a Central Asian ministry of health is exactly the kind of deliverable that supports both goals.

The GCC as a whole has been moving toward digital health integration, with the UAE building out its own telemedicine infrastructure and Bahrain advancing electronic health records across its system. But this particular announcement goes further geographically than most. It demonstrates that the infrastructure Saudi Arabia built domestically is now capable of operating at an international scale, and that other governments are willing to connect their systems to it.

AlJalajel’s visit to the Digital Health Center in Tashkent before the launch also suggests this is the beginning of a longer relationship, not a one-off ceremony. Watch for further agreements with Uzbekistan, and possibly other Central Asian states, as Saudi health diplomacy continues to expand its reach.

The post Saudi Arabia connects Seha Virtual Hospital to Uzbekistan in a landmark digital health deal appeared first on DH Arab.

This is not a routine partnership announcement. It brings together two organisations that sit on different sides of the care equation: a clinical network with significant infrastructure and a civil society organisation with deep community roots. That combination, when it works, tends to produce results that neither side could achieve alone.

How will it work?

While the full operational details are still emerging, MoUs of this type typically establish shared protocols, referral pathways, and joint programmes. Based on the organisations involved, the partnership is expected to cover:

• Coordinated referrals between SAKINA’s clinical teams and Emirates Autism Society’s community programmes
• Joint development of specialised rehabilitation services for individuals with ASD
• Improved access to mental health support for autistic individuals and their families
• Knowledge-sharing between clinical professionals and community-based specialists

The goal, in plain terms, is to reduce the fragmentation that families with autistic members so often experience when trying to access consistent, long-term care.

Why does it matter?

Autism Spectrum Disorder affects a significant and growing number of individuals across the GCC. But access to quality, coordinated care has historically been uneven. Families frequently move between providers, repeat assessments, and encounter gaps between clinical treatment and community support. A formal agreement like this one creates accountability and structure where informal coordination often falls short.

For the UAE specifically, this kind of integration aligns with the country’s broader health ambitions. The UAE’s national health strategy has placed considerable emphasis on specialised and preventive care, and mental health has moved from the margins to a stated priority. PureHealth, as one of the region’s largest integrated healthcare platforms, has the scale to make agreements like this one operationally meaningful rather than symbolic.

The context

SEHA runs one of the most extensive public healthcare networks in Abu Dhabi, and SAKINA sits within that structure as its dedicated mental health arm. The Emirates Autism Society, meanwhile, has been one of the most active advocacy and support organisations for the autism community in the UAE for years. So this is not two unfamiliar parties coming together. It’s a formalisation of what should be a natural alliance.

Across the GCC, there is growing recognition that mental health and neurodevelopmental conditions require long-term, community-embedded models of care, not just clinical episodes. This MoU is a step in that direction. Whether it delivers on its promise will depend on implementation, but the structure is at least pointed the right way.

The post SAKINA and Emirates Autism Society join forces to close the gap in autism care appeared first on DH Arab.

The platform lets patients search for physicians, book appointments online, and manage their healthcare interactions through a single digital interface. On the provider side, clinics and doctors get a tool to handle scheduling and patient engagement without paper registers or phone queues. It’s a model that has worked across the broader Arab world, from Vezeeta in Egypt to Doctori in the UAE, and DoctorBook is now making the case that Syria is ready for the same shift.

What will the money be used for?

• Technology development and platform improvements
• Expansion of the healthcare provider network
• User experience upgrades for patients
• Growth across the Syrian market

Why does it matter?

Syria’s healthcare system has spent over a decade under severe strain. Digital infrastructure for patient access is almost nonexistent compared to neighbouring countries. A platform that reduces friction between patients and providers, even modestly, addresses a real and urgent gap. And while $16,000 will not rebuild a health system, it signals that investors, however small, are beginning to back Syrian tech founders again.

The context

Syria’s startup ecosystem is early but moving. Recent investments in local technology companies have brought cautious optimism, and digital adoption across the country is growing. DoctorBook is entering a market with low competition and high need. The founders will need significantly more capital to scale, but a working product and early traction could position them well for a seed round. Across the GCC, digital health has attracted billions in investment over the past five years. Syria’s moment may still be some distance away, but startups like DoctorBook are laying the groundwork.

The post DoctorBook raises $16,000 pre-seed to digitise healthcare access in Syria appeared first on DH Arab.